This memo issues no Long / Short / Watchlist / Avoid verdict. It scores every Criteria and blocks on none of them. Whether the analysis justifies a position is a question about a particular book, and the book decides.
How to read this
This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict.
Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored, and never block — they inform timing, sizing or a future strategy. A missing input is INDETERMINATE, never FAIL.
Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term estimates and the name's own multiple history with its percentile stated. Neither replaces the other. Sensitivity is run over the exit multiple, never over scenario probabilities.
Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.
Key findings
- ACCOUNTING QUALITY: 62% of GMED's $313.8m FY2025 operating-income increase is the non-recurrence of the NuVasive inventory fair-value step-up ($215.4m in FY2024 vs $19.5m in FY2025). Ex step-up, gross margin is flat at ~67-68%.
- ACCOUNTING QUALITY: FY2025 GAAP net income of $537.9m includes a $117.7m non-cash, largely non-taxable bargain purchase gain from recognising Nevro's deferred tax assets. It sits BELOW the operating-income line, so operating income is clean; GAAP EPS is not. Ex-gain GAAP diluted EPS is ~$3.06, not $3.92.
- SCREEN ERROR: TTM revenue was understated by $228.2m (-7.4%) because the scanner summed four TAGGED quarterly periods rather than four CONSECUTIVE ones - Q4 2025 is not tagged (no Q4 10-Q exists) and a Q1 was duplicated.
- SCREEN ERROR: gross margin reported as 34.7% is FY2023 GrossProfit divided by FY2025 revenue. Actual FY2025 gross margin is 67.4%.
- SCREEN ERROR: net cash understated by $169.4m - long-term marketable securities were omitted.
- MECHANISM: five consecutive quarters of monotonic organic acceleration, every figure company-disclosed: -1.4% (Q1'25), +3.3%, +7.0%, +10.6%, +13.2% (Q1'26). US Spine has grown 10% for three straight quarters.
- MECHANISM: base-business Adjusted EBITDA margin (Nevro carved out, no step-up on either side) rose from 29.2% to 33.4% in FY2025 and hit 35.7% in Q4. FY2026 non-GAAP EPS guidance has been raised twice in six months, from $4.30-4.40 to $4.70-4.80.
- REFERENCE-BOOK DISAGREEMENT: 'NVRO impaired' is CORRECT on the business - Nevro TTM revenue is -7.9% vs its last standalone year - but there is no impairment to take: the deal produced a $117.7m bargain purchase gain, NOT goodwill, and total Nevro intangibles are $56.0m. Nevro generated $21.2m of Adjusted EBITDA in Q4 2025 alone against a $252.5m purchase price.
- REFERENCE-BOOK DISAGREEMENT: 'spine market rolling' is NOT SUPPORTED. GMED base business accelerated to +13.2% and ATEC, the pure-play US spine comparator, grew +13.5% in the same quarter - both far above any plausible 4-6% market rate.
- VALUATION: the screen's +42.0pp margin corrects to +2.8pp. The 39pp reduction is 33.7pp from counting M&A as organic capability and 11.3pp from anchoring the exit multiple to that same acquired growth rate; the data errors run the other way and are worth +5.7pp combined.
- LIQUIDITY: no investable options market. The March-2027 chain carries 13 contracts of total open interest across 48 strikes. Common stock is the only vehicle.
Sections
Disclosed limitations
- No Street consensus anywhere in this memo - Alpha Vantage EARNINGS_ESTIMATES quota was exhausted on 2026-07-29 and the API returned its rate-limit notice. Every forward figure is company guidance (labelled) or a house estimate (labelled).
- Mention-frequency was run on the SEC EDGAR 8-K Ex-99.1 quarterly earnings-release corpus (10 quarters, 2023Q4-2026Q1), not Alpha Vantage transcripts, because the transcript quota was exhausted. One source used consistently across the whole series, per references/mention-frequency.md. Raw counts for the emerging terms are 1-3; every emerging read is corroborated by an independent filing record.
- No FY2027 guidance exists; the FY2027 revenue figure in the 12-month target is a house extension, labelled at the point of use.
- Pro-forma NuVasive-combined revenue is not disclosed in the FY2025 10-K, so a clean FY2022-FY2025 organic CAGR spanning both mergers cannot be constructed. The TTM organic figure is used instead and its window is stated.
- Consolidated ADV is not available from the Alpaca IEX feed; only the partial-tape figure ($9.5m/day) is reported, labelled as partial.
- GMED discloses no Excelsius placement counts, procedure volumes or franchise-level margins. None are estimated.
- $100.3m of business acquisition liabilities (contingent consideration) are treated as non-debt in the headline net cash of $799.3m. On the alternative treatment net cash is $699.0m; the effect on the required CAGR is under 20bp and was not separately modelled.